Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New hope for kids with rare kidney diseases: drug trial aims to cut protein leak
Disease control Recruiting nowThis study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New shot could tame rare metabolic disease
Disease control Recruiting nowThis Phase 3 trial tests pegtibatinase, an enzyme given as a shot, in 70 people aged 12–65 with classical homocystinuria. The goal is to see if it safely lowers high homocysteine levels when added to standard care. Participants receive either the drug or a placebo for 24 weeks.
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC